Nile Therapeutics will merge with Capricor to become new company focused on heart disease

8 July 2013

USA-based Nile Therapeutics (OTCQB: NLTX) has today (July 8) announced a merger with privately-held Californian biotechnology company Capricor to become a combined company called Capricor Therapeutics, in an all stock transaction.

The merger will take the form of a stock-for-stock reverse merger intended to qualify as a tax-free reorganization. Under the terms of the deal, Nile will issue to Capricor stockholders shares of Nile common stock so that Capricor stockholders will own around 90% of the combined company's outstanding shares, and Nile stockholders about 10%. Options of Capricor will be assumed by Nile and become options to acquire stock of Nile. The closing is subject to the satisfaction of certain conditions, including Nile and Capricor stockholder approval.

Capricor's lead product candidate is CAP-1002, a proprietary allogeneic adult stem cell therapy for the treatment of heart damage. The product is derived from donor heart tissue. Capricor, which develops cardiac stem cell (CDC) therapeutics to repair damaged heart muscle, will become a wholly-owned subsidiary of Nile Therapeutics. The merger will create a publicly traded company focused on the development of novel treatments to prevent and treat heart disease, as well as having a core expertise in regenerative medicine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology